- Rivista:
- European Journal of Haematology 90:4-345:348 2013 - I.F. 2,99
- AUTORI: Voso MT., Breccia M., Lunghi M., Poloni A., Niscola P., Bari A. et al.
In patients with myelodysplastic syndromes (MDS), the likelihood of having a sustained response to azacitidine is increased by maximizing treatment duration. This is important